NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.

By J. Rubnitz, H. Inaba, R. Ribeiro, S. Pounds, Barbara Rooney, Teresa Bell, Ching-Hon Pui, W. Leung. Journal of Clinical Oncology, 2010

632 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent anti-tumor activity (2017, neutral): “Functional NK cells can be derived from several sources.(9, 12, 13) Autologous NK cells can be reproducibly generated in vitro, but have limited activity against autologous tumors, (14, 15) which may not be overcome by CAR engineering.”
Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells (2012, background): “NK cells have therapeutic potential for a wide variety of human malignancies, including sarcomas [9,10], myeloma [11], carcinomas [12,13,14,15], lymphomas [16], and leukemias [14,17,18].”